Pentoxifylline preloading reduces endothelial injury and permeability in cardiopulmonary bypass

ASAIO Journal

Volumn 42, Issue 5, 1996, Pages

  Tsang, Geoffrey M K ^a   Allen, S ^a   Pagano, Domenico ^a   Wong, Carl ^a   Graham, Timothy R ^a   Bonser, Robert S ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD; CARDIOLOGY; CARDIOVASCULAR SYSTEM; CELLS; DRUG THERAPY; PROTEINS; SURGERY;

CARDIOPULMONARY BYPASS; ENDOTHELIAL INJURY; ENDOTHELIAL PERMEABILITY; INTERLEUKIN; LEUKOTRIENE; PENTOXIFYLLINE; URINARY ALBUMIN EXCRETION; VON WILLEBRAND FACTOR;

CARDIOVASCULAR SURGERY;

PENTOXIFYLLINE;

BLOOD VESSEL PERMEABILITY; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY BYPASS GRAFT; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENDOTHELIUM INJURY; FEMALE; HEART PRELOAD; HUMAN; MALE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; VASCULAR ENDOTHELIUM;

EID: 0030250820     PISSN: 10582916     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002480-199609000-00025     Document Type: Review

References (61)

1. Kirklin JW, Barrett-Boyes BG: Hypothermia, circulatory arrest and cardiopulmonary bypass, in Kirklin JW, Barrett-Boyes BC (eds), Cardiac Surgery, New York, Churchill Livingston, 1993, pp. 61-127.
2. Kirklin JK, Westaby S, Blackstone EH, Kirklin JW, Chenoweth DE, Pacifico AD: Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 86:845-857, 1983.
3. Steinberg JB, Kapelanski DP, Olson JD, Weiler JM: Cytokineand complement levels in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 106: 1008-1016, 1993.
4. Kalfin RE, Engelman RM, Rousou JA, et al: Induction of interleukin-8 expression during cardiopulmonary bypass. Circulation 88(II):401-406, 1993.
5. Hind CRK, Griffin JF, Pack S, et al: Effect of cardiopulmonary bypass on circulating concentrations of leucocyte elastase and free radical activity. Cardiovasc Res 22: 37-41, 1988.
6. Utoh J, Yamamoto T, Kambara T, Goto H, Miyauchi Y: Perioperative alteration of neutrophil function after open heart and other major surgeries. J Cardiovasc Surg 30: 692-695, 1989.
7. Braude S, Nolop KP, Fleming JS, Krausz T, Taylor KM, Royston D: Increased pulmonary transvascular protein flux after canine cardiopulmonary bypass: association with lung neutrophil sequestration and tissue peroxidation. Am Rev Respir Dis 134: 867-872, 1986.
8. Smith EEJ, Naftel DC, Blackstone EH, Kirklin JW: Microvascular permeability after cardiopulmonary bypass: an experimental study. J Thorac Cardiovasc Surg 94: 225-233, 1987.
9. Ratcliff NB, Young WG, Hackel DB, Mikat, Wilson JW: Pulmonary injury secondary to extracorporeal circulation. An ultrastructure study. J Thorac Cardiovasc Surg 65: 425-432, 1973.
10. Anyanwu E, Dittrich H, Giesking R, Enders HJ: Ultrastructure changes in the human lung following cardiopulmonary bypass. Basic Res Cardiol 77: 309-322, 1982.
11. Boneu B, Abbal M, Plante J, Bierme R: Factor VIII complex and endothelial damage. Lancet 1: 1430, 1975.
12. Porta M, Townsend C, Clover GM: Evidence for functional endothelial cell damage in early diabetic retinopathy. Diabetologia 20: 597-601, 1981.
13. Giustolisi R, Lombardo T, Musso R, Cacciola E: Factor VIII antigen plasma levels in diabetes mellitus. Enhanced endothelial release and storage. Thromb Haemost 44: 46, 1980.
14. Belch JJF, Zoma AA, Richards IM, McLaughlin K, Forbes CD, Sturrock RD: Vascular damage and Factor VIII related antigen in the rheumatic diseases. Rheumatol Int 7: 107-111, 1987.
15. Jones DK, Luddington R, Higenbottam TW, et al: Changes in Factor VIII proteins after cardiopulmonary bypass in man suggests endothelial damage. Thromb Haemost 60: 199-204, 1988.
16. Bland AD, McCollum CN: von Willebrand factor, endothelial cell damage and atherosclerosis, Eur J Vasc Surg 8: 10-15, 1994.
17. Gosling P, Shearman CP: Increased levels of urinary proteins: markers of vascular permeability? Ann Clin Biochem 25: 150-151, 1988.
18. Gosling P, Sutcliffe AJ, Cooper MACS, Jones AF: Burn and trauma associated proteinuria: the role of lipid peroxidation, renin and myoglobin. Ann Clin Biochem 25: 53-59, 1988.
19. Shearman CP, Gosling P, Simms MH: Glomerular permeability to large molecules: a marker for vascular permeability? Br J Surg 75: 1273, 1988.
20. Gosling P, Hughes EA, Reynolds TM, Fox JP: Microalbuminuria is an early response following acute myocardial infarction, Eur Heart J 12: 508-513, 1991.
21. Hickey NC, Shearman CP, Gosling P, et al: Assessment of intermittent claudication by quantitative estimation of exercise induced microalbuminuria. Eur J Vasc Surg 4: 603-606, 1990.
22. Smith FCT, Gosling P, Sanghera K, Green M, Paterson IS, Shearman CP: Microproteinuria predicts the severity of the systemic effects of reperfusion injury following infrarenal aortic aneurysm surgery. Ann Vasc Surg 8: 1-5, 1994.
23. Tsang GMK, Sanghera K, Gosling P, et al: Pharmacological reduction of the systemically damaging effects of local ischaemia. Eur J Vasc Surg 8:205-208, 1994.
24. Welsh CH, Lien D, Worthen GS, Weil JV: Pentoxifylline decreases endotoxin-induced pulmonary neutrophil sequestration and extravascular protein accumulation in the dog, in Mandell G, Novick W (eds), Proceedings of a Symposium, Pentoxifylline and Leukocyte Function, Somerville, NJ, Hoechst-Roussel Pharm, Inc., 1988, pp. 190-198.
25. Ishizaka A, Harada H, Stephens KE: Preventive effects of pentoxifylline on E. coli induced acute lung injury and multi-organ damage in guinea pigs, in Mandell G, Novick W (eds), Proceedings of a Symposium, Pentoxifylline and Leukocyte Function, Somerville, NJ, Hoechst-Roussel Pharm, Inc., 1988, pp. 211-223.
26. Ward A, Clissold SP: Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 34: 50-97, 1987.
27. Porter JM, Cutler BS, Lee BY, et al: Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J 104: 66-72, 1982.
28. Rosenfeld B, Sendak M, Breslow M, Toung T, Traystman R: Effects of pentoxifylline on proteolytic induced acute lung injury, in Mandell G, Novick W (eds), Proceedings of a Symposium, Pentoxifylline and Leukocyte Function, Somerville, NJ, Hoechst-Roussel Pharm, Inc., 1988, pp. 234-237.
29. Dauber IM, Welsh CH, Weil JV: Cardiopulmonary bypass-induced pulmonary and coronary vascular injury is decreased by pentoxifylline, in Mandell G, Novick W (eds), Proceedings of a Symposium, Pentoxifylline and Leukocyte Function, Somerville, NJ, Hoechst-Roussel Pharm Inc., 1988, pp. 199-210.
30. Bessler H, Gigal R, Djaldetti M, Zahavi I: Effects of pentoxifylline on the phagocytic activity, cAMP levels and Superoxide anion production by monocytes and polymorphonuclear cells. J Leukocyte Biol 40: 747-754, 1986.
31. Ciuffetti G, Mercuri M, Ott C, et al: Use of pentoxifylline as an inhibitor of free radical generation in peripheral vascular disease. Results of a double-blind placebo-controlled study. Eur J Clin Pharmacol 41: 1-5, 1991.
32. Sullivan GW, Carper HT, Novick WJ, Mandell GL: Inhibition of the inflammatory action of interleukin-1 and tumour necrosis factor (alpha) on neutrophil function by pentoxifylline. Infect Immun 56: 1722-1729, 1988.
33. Sullivan GW, Carper HT, Novick WJ, Mandell GL: Pentoxifylline inhibits the inflammatory effects of endotoxin and endotoxin induced cytokines on neutrophil function, in Mandell G, Novick W (eds), Proceedings of a Symposium, Pentoxifylline and Leukocyte Function, Somerville, NJ, Hoechst-Roussel Pharm, Inc., 1988, pp. 37-48.
34. Rose RF, Hirschhorn R, Weissmann G, Cronstein BN: Adenosine promotes promotes neutrophil neutrophil chemotaxis. J Exp Med 167: 1186-1194, 1988.
35. Bertocchi F, Proerpio P, Dejana E: The effect of pentoxifylline on polymorphonuclear cell adhesion to cultured endothelial cells. A preliminary report, in Mandell G, Novick W (eds), Proceedings of a Symposium, Pentoxifylline and Leukocyte Function, Somerville, NJ, Hoechst-Roussel Pharm, Inc., 1988, pp. 67-74.
36. Till GO, Warren JS, Gannon DE, et al: Effects of pentoxifylline on phagocyte responses in vitro and acute and chronic inflammatory reactions in vivo.in Mandell G, Novick W (eds), Proceedings of a Symposium, Pentoxifylline and Leukocyte Function. Somerville, NJ, Hoechst-Roussel Pharm, Inc., 1988, pp. 124-137.
37. Zabel P, Wolter DT, Schade UF, Schonharting MM: Oxpentifylline in endotoxaemia. Lancet 2: 1474-1477, 1989.
38. Tighe D, Moss R, Hynd J, et al: Pentoxifylline reverses hemodynamic and histological changes associated with peritonitis in pigs.in Mandell G, Novick W (eds), Proceedings of a Symposium, Pentoxifylline and Leukocyte Function. Somerville, NJ, Hoechst-Roussel Pharm, Inc., 1988, pp. 184-189.
39. Rowe DJF, Dawnay A, Watts GF: Microalbuminuria in diabetes mellitus: review and recommendations for the measurements of albumin in urine. Ann Clin Biochem 27: 297-312, 1990.
40. Matthews JNS, Altman DG, Campbell MJ, Royston P: Analysis of serial measurements in medical research. Br Med J 300: 230-235, 1990.
41. Salama A, Hugo F, Heinrich D, et al: Deposition of terminal C5b-9 complement complexes on erythrocytes and leukocytes during cardiopulmonary bypass. N Engl J Med 318: 408-414, 1988.
42. Ford-Hutchinson AW, Bray MA, Doig M, Shipley ME, Smith MJ: Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonulear leukocytes. Nature 226: 264-265, 1980.
43. Butler J, Baigrie RJ, Parker D, et al: Systemic inflammatory response to cardiopulmonary bypass: a pilot study of the effects of pentoxifylline. Respir Med 87: 285-288, 1993.
44. Tennenberg SD, Clardy CW, Bailey WW, Solomkin JS: Complement activation and lung permeabiltiy during cardiopulmonary bypass. Ann Thorac Surg 50: 597-601, 1990.
45. Friedman M, Sellke FW, Wang SY, Weintraub RM, Johnson RG: Parameters of pulmonary injury after total or partial cardiopulmonary bypass. Circulation 90: II262-II268, 1994.
46. Butler J, Pillai R, Rocker M, Westaby S, Parker D, Shale DJ: Effect of cardiopulmonary bypass on systemoc release of neutrophil elastase and tumour necrosis factor. J Thorac Cardiovasc Surg 105: 25-30, 1993.
47. Regragui IA, Izzat MB, Birdi I, Lapsley M, Bryan AJ, Angelini CD: Cardiopulmonary bypass perfusion temperature does not influence perioperative renal function. Ann Thorac Surg 60: 160-164, 1995.
48. Hashimoto K, Miyamoto H, Suzuki K, et al: Evidence of organ damage following cardiopulmonary bypass. The role of elastase and vasoactive mediators. J Thorac Cardiovasc Surg 104: 666-672, 1992.
49. Hashimoto K, Nomura K, Nakano M, Sasaki T, Kurosawa H: Pharmacological intervention for renal protection during cardiopulmonary bypass. Heart Vessels 8: 203-210, 1993.
50. Ip-Yam PC, Murphy S, Baines M, Fox MA, Desmond MJ, Innes PA: Renal function and proteinuria after cardiopulmonary bypass: the effects of temperature and mannitol. Anesth Analg 78: 842-847, 1994.
51. Shearman CP, Gosling P, Walker KJ. Is low level proteinuria an early predictor of severity of acute pancreatitis? J Clin Pathol 42: 1132-1135, 1989.
52. Hickey NC, Hudlicka O, Gosling P, et al: Intermittent claudication incites systemic neutrophil activation and increased vascular permeability. Br J Surg 80: 181-184, 1993.
53. Klausner JM, Patterson IS, Goldman G, et al: Post ischaemic renal injury is mediated by neutrophils and leukotrienes. Am J Physiol 256: F794-F802, 1989.
54. Jaffe EA, Hoyer LW, Nachman RL: Synthesis of von Willebrand factor by cultured human endothelial cells. Proc Natl Acad Sci USA 71: 1906-1909, 1974.
55. Sporn LA, Marder VJ, Wagner DD: Differing polarity of the constituive and regulated secretory pathways for von Willebrand factor in endothelial cells. J Cell Biol 108: 1283-1289, 1989.
56. Giddings JC, Brookes LR, Piovella F, Bloom AL: Immunohistochemical comparison of platelet factor 4 (PF4), fibronectin (Fn) and Factor VIII related antigen (VIII:RAg) in human platelet granules. Br J Haematol 52: 79-88, 1982.
57. Ginsberg D: The von Willebrand factor gene and genetics of von Willebrand's disease. Mayo Clin Proc 66: 506-515, 1991.
58. Valen G, Blomback M, Sellei P, Lindblom D, Vaage J: Release of von Willebrand factor by cardiopulmonary bypass, but not by cardioplegia in open heart surgery. Thromb Res 73: 21-29, 1994.
59. Holdright DR, Hunt BJ, Parratt R, et al: The effects of cardiopulmonary bypass on systemic and coronary levels of von Willebrand factor. Eur J Cardiothorac Surg 9:18-21, 1995.
60. Turner-Gomes SO, Andrew MA, Coles J, Trusler GA, Williams WG, Rabinovitch M: Abnormalities in von Willebrand factor and antithrombin III after cardiopulmonary bypass operations for congenital heart disease. J Thorac Cardiovasc Surg 103: 87-97, 1992.
61. Bland AD: von Willebrand factor as a marker of injury to the endothelium in inflammatory vascular disease. J Rheumatol 20: 1469-1471, 1993.